Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) EBIT (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed EBIT for 8 consecutive years, with -$27.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT rose 20.26% year-over-year to -$27.5 million, compared with a TTM value of -$98.9 million through Sep 2025, down 282.07%, and an annual FY2024 reading of -$36.4 million, up 66.15% over the prior year.
  • EBIT was -$27.5 million for Q3 2025 at X4 Pharmaceuticals, down from -$26.2 million in the prior quarter.
  • Across five years, EBIT topped out at $71.1 million in Q2 2024 and bottomed at -$37.3 million in Q1 2024.
  • Average EBIT over 5 years is -$20.0 million, with a median of -$25.6 million recorded in 2022.
  • The sharpest move saw EBIT soared 375.54% in 2024, then plummeted 136.89% in 2025.
  • Year by year, EBIT stood at -$29.1 million in 2021, then rose by 11.97% to -$25.6 million in 2022, then rose by 1.48% to -$25.2 million in 2023, then plummeted by 41.73% to -$35.7 million in 2024, then rose by 22.98% to -$27.5 million in 2025.
  • Business Quant data shows EBIT for XFOR at -$27.5 million in Q3 2025, -$26.2 million in Q2 2025, and -$9.4 million in Q1 2025.